Advanced NanoTherapies

Advanced NanoTherapies, Inc.Founded in 2018 in Los Gatos, California, Advanced NanoTherapies, Inc. focuses on developing advanced medical devices. The CEO and founder, Marwan Berrada-Sounni, has a history of innovation in the medical field. Advanced NanoTherapies specializes in innovative medical solutions, primarily focusing on their flagship product, the SirPlux Duo Drug Coated Balloon (DCB). This next-generation technology delivers two synergistic drugs, Sirolimus and Paclitaxel, simultaneously, enhancing the prevention of restenosis for patients suffering from coronary artery disease (CAD) and peripheral artery disease (PAD).) nanoparticle drug delivery platform, promoting sustained bioavailability and improved tissue retention at the lesion site. Their products target healthcare providers, particularly hospitals and specialized clinics across North America and Europe, and aim to improve patient outcomes by providing stent-like performance without associated complications. Advanced NanoTherapies operates within a specialized medical device market, utilizing a B2B model that involves direct transactions with healthcare institutions. Revenue is generated through sales of their proprietary products, particularly the SirPlux Duo DCB, which is a front-line therapy for treating arterial diseases. The company engages in strategic partnerships to integrate their technologies into clinical practices, establishing a robust distribution network, while revenue structures are based on negotiated contracts with hospitals that may include volume-based or tiered pricing agreements. In June 2026, Advanced NanoTherapies, Inc.S. FDA IDE approvals, progress coronary clinical trials, and extend into below-the-knee peripheral vascular indications.

1. Series B

   Jun 2, 2026

   Amount

   $31M

   Investors

   Locked

2. Seed

   Oct 13, 2020

   Amount

   Undisclosed

   Investors

   Locked